AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01403675 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ovarian autotransplantation
Description: There are two ways to transplant the thawed ovarian tissue back into a woman's body. It can be put back inside the abdomen, close to the natural location of the ovaries, or the tissue can be put under the skin of the abdomen. After you have had the transplant, your hormone function will be tested every month. Each month, you will have a blood draw to measure hormones and an ultrasound to see how the tissue is growing. These monthly visits will continue until you have normal hormone levels. If the transplant is successful, it is expected that your hormones would return to normal in 3 - 7 months. If your hormone levels return and stay regular for three months, then Dr. Kim will talk to you about trying to get pregnant. The method of getting pregnant will depend on the type of transplantation surgery you had and your current medical condition. You will have weekly blood tests and other tests to determine the best way to get pregnant.
Study NCT02546856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure (HF) nurse up-titration
Description: Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines with cardiologist prescription and support.
Study NCT02546856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heart Failure (HF) cardiologist up-titration
Description: Up-titration of Beta-Blocker (BB), Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II Receptor Blocker (ARB) and Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure De Novo patients with Left Ventricular Ejection Fraction (LVEF)≤ 40%, following a protocol based on 2012 European Society of Cardiology (ESC) Heart Failure (HF) guidelines. Drugs are prescribed and titrated by the cardiologist.
Study NCT02298270 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: The Relaxation Response Resiliency Program (3RP) via Skype
Description: 8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
Study NCT02298270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Relaxation Response Resiliency Program (3RP) via Skype
Description: 8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
Study NCT03015350 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: Measurement of blood desflurane level during one lung ventilation
Study NCT03015350 — intervention group
Intervention type: DRUG
Intervention: Desflurane
Description: Measurement of blood desflurane level during one lung ventilation
Study NCT02324530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP)
Description: CT simulation with and without CPAP
Study NCT03627455 — intervention group
Intervention type: OTHER
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention
Study NCT03121742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ecological Momentary Intervention
Description: Patients will be taught four therapeutic intervention skills based on positive psychology and cognitive behavioral therapy. They will then be prompted to complete these interventions on a smartphone four times per day (and as needed) for the duration of their inpatient care and for 28 days afterwards.
Study NCT03121742 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Standard care as part of inpatient hospitalization.
Study NCT03121742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Standard care as part of inpatient hospitalization.
Study NCT04610242 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: skin test
Description: For skin prick tests (SPT), rituximab solution of 1mg/ml was applied on the volar aspect of the forearm. For intradermal tests (IDT), 0.02 mL of a 1:100 dilution (0.1mg/ml) of full-strength solution (10mg/ml) was injected first. If the result was negative, a 1:10 dilution（1mg/ml）was then used.~As to the desensitization protocol, three solutions with different concentrations are delivered in 12 consecutive steps, each step increasing the rate of drug administration by 2- to 2.5-fold. Solution 1 is a 100-fold dilution (0.01mg/ml) of the final target concentration, solution 2 is a 10-fold dilution (0.1mg/ml) of the final target concentration, and the concentration of solution 3 is the target concentration (1mg/ml). Each step takes 15 minutes until the target rate of 200ml/h is reached, and the final step is prolonged to complete the target dose. The whole procedure takes about 5.5 hours.
Study NCT02082067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal
Description: Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert in adductor canal through tuohy needle (18G, 100mm length) under ultrasound guidance.
Study NCT02082067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral
Description: Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert between femoral nerve and femoral artery through tuohy needle (18G, 100mm length) under ultrasound guidance.
Study NCT02082067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.
Study NCT02082067 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal Anesthesia
Description: Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.
Study NCT02082067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.
Study NCT02082067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local anesthetic infusion
Description: Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.
Study NCT02082067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic infusion
Description: Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.
Study NCT02082067 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous analgesia
Description: Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.
Study NCT02082067 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous analgesia
Description: Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.
Study NCT02082067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous analgesia
Description: Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.
Study NCT02082067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0,75%
Study NCT02082067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0,75%
Study NCT02082067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0,5%
Study NCT02082067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine 0,5%
Study NCT02082067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0,5%
Study NCT02082067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0,125%
Study NCT02082067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine 0,125%
Study NCT02082067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 30mg
Study NCT02082067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac 30mg
Study NCT05023902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates
Description: Pilates has been performed to all participants two times a week in order to compare the effects of NIA
Study NCT05023902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Integrative Action
Description: NIA was the experimental group of this study.
Study NCT02082067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac 30mg
Study NCT02082067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Study NCT02082067 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Study NCT02082067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT02082067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stimulong sono, Pajunk, Germany
Study NCT02082067 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stimulong sono, Pajunk, Germany
Study NCT00667758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 3-5 mg s.c. on days 1-5
Study NCT03193437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label Selinexor
Description: Selinexor 40 mg oral tablets will be administered twice weekly, either on Monday/Wednesday, Tuesday/Thursday, Wednesday/Friday, Thursday/Saturday, or Friday/Sunday in a 3-weeks-on and 1-week-off schedule.
Study NCT03918408 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PXL-330 Platinum device for crosslinking with Peschke ribofflavin solution
Description: Riboflavin will be used to load the cornea, followed by UV-A crosslinking of the cornea
Study NCT02819661 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caesarean section
Description: Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).
Study NCT03170739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine
Description: Dopamine given during surgery.
Study NCT03076645 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitator support and education
Description: Group engaged with facilitator support and education
Study NCT02819661 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with intrathecal morphine
Description: is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space
Study NCT00667758 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3-5 ml NaCl s.c. on days 1-5
Study NCT01651130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg
Study NCT03660371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPV/MP
Description: Internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
Study NCT03660371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PPV without MP
Description: No internal limiting membrane (ILM) peeling during vitrectomy for the indication of diabetic vitreous hemorrhaging
Study NCT00591227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: insulin aspart: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.
Study NCT00591227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin detemir
Description: insulin detemir: insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER.~If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.
Study NCT00130208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulodexide
Description: 100 mg sulodexide gelcaps
Study NCT00130208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg gelcap
Study NCT04015297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: raman analysis
Description: negative or pozitive
Study NCT02942810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 5222
Description: IV infusion over a period of 60 minutes
Study NCT02920476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5. TAS-102 is to be taken within 1 hour of completion of morning and evening meals.~Days 6 through 7: Rest~Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.~Days 13 through 28: Rest
Study NCT05092035 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: single high-fidelity expiratory CO2 analysis
Description: in addition to regular pulmonary function testing a real-time high-fidelity assessment of expiratory CO2 will be performed
Study NCT02119637 — intervention group
Intervention type: DEVICE
Intervention: Transcranial magnetic stimulation (TMS)
Description: 1 Hz rTMS for 20 minutes. TMS sessions were separated by at least 24 hours.
Study NCT02119637 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: Anatomical MRI, resting state MRI and functional MRI using gentle brushing and finger movement
Study NCT00635687 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: transient elastography measure - Liver stiffness
Study NCT02683291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Study NCT02683291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Study NCT02683291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study NCT02683291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate
Study NCT02683291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 30mg/day
Study NCT02683291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone 30mg/day
Study NCT02683291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %
Study NCT02683291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %
Study NCT02683291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
Study NCT02683291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
Study NCT01581892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteosynthesis
Description: To mix the cell suspension with osteogenic matrix and to use sheet and nails in order to consolidate the fracture
Study NCT04540068 — intervention group
Intervention type: DRUG
Intervention: Transforaminal Epidural Injection
Description: Injections above L3 will contain 1,5 ml lidocaine 1% and 10 mg dexamethasone and injections at L3 or below will contain 1,5 ml lidocaine 2% and 40mg methylprednisolone acetate in accordance with current Dutch anesthesiologic guidelines for usual care.
Study NCT00307723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.
Study NCT00307723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.
Study NCT00307723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.
Study NCT00307723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.
Study NCT00307723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Monday through Friday ending on day 38 of cycle 1
Study NCT01534754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine plus Lactobacillus casei
Description: Active Mesalazine 800 mg, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
Study NCT01534754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mesalazine placebo plus Lactobacillus casei placebo
Description: Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for oe year.
Study NCT01534754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine 800 mg
Description: Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.
Study NCT01534754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus casei
Description: Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
Study NCT03797196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose tacrolimus in combination with everolimus
Description: a low exposure Tacrolimus once-daily (Envarsus®) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
Study NCT03797196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dose tacrolimus with mycophenolate mofetil
Description: A standard Tacrolimus once-daily (Envarsus) regimen in combination with Everolimus will be evaluated in elderly transplant recipients
Study NCT03057535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Study NCT03057535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride
Study NCT02599662 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 10 Gy Low-KV IORT
Description: : intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
Study NCT02599662 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 15 Gy Low-KV IORT
Description: intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
Study NCT02599662 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: 20 GY Low-KV IORT
Description: intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
Study NCT01633307 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Teaching program
Study NCT01220960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: art therapy
Description: Art therapy sessions, 2 hours in duration, 1 session/week, 8 continuous weeks of sessions. Each group will be limited to eight women as space is limited.
Study NCT02836587 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: The interventional program will last 8 weeks with the intensity of two 60-minutes lectures a week. Training sessions will be delivered by a physiotherapist to small groups of patients (3-5). Participants will receive individualized exercises which will be focused on main 4 types - stance exercises, gait and transition exercises and strength exercises especially focused on muscle strength of the lower extremities. The difficulty level will be increased progressively after participant's ability to complete each exercise independently (e.g. eyes closed, exercises on balance equipment - wobble board, foam etc., addition of a secondary cognitive task). The training session will consist of a ten-minute warm-up followed by five-minute stretching, 30 minutes of balance training and 15 minutes of stretching and relaxation.
Study NCT06352762 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Strengthening and stretching exercises for lower and upper extremity muscles, hip and trunk stabilization training, balance training, gait training, upper extremity functional skills training, endurance training and coordination training were given. Exercises were planned according to the developmental stage. Sessions were applied 3 days a week and 45 minutes for 5 weeks, for a total of 15 sessions.